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A B S T R A C T  
Background: The increased frequency and management of antibiotic resistance pattern in urinary tract infection (UTI) is a 
challenging task for the clinicians. Therefore, the current study was planned to identify the microbial etiology of UTI and t he most 
suitable antibiotics used. The objective of the study was to assess the frequency of antimicrobial sensitivity pattern in patients with 
urinary tract infection. 
Material and Methods: This cross-sectional study was carried out at Al Sayed Hospital, Kidney Centre, Rawalpindi over a period of 
seven months i.e. June 30, 2018 to January 30, 2019. A total of 152 patients were enrolled according to the inclusion and exclusion 
criteria of the study. Urine culture proceedings were done as per latest recommended guidelines of Clinical and Laboratory Standard 
Institute (CLSI) for UTI. 
Results: Highest sensitivity was observed for carbapenems (83.5%), followed by polymyxin B (72.3%), phosphonic acid derivatives 
(65.8%), aminoglycoside group (65.7%), extended spectrum penicillin (63.1%), imidazolidinedione (59.9%) and tetracycline (59.9%) 
groups. The least sensitivity was observed for Oxazolidinone (linezolid) (14.5%), teicoplanin (13.8%), tigecycline (10.5%) and first-
generation cephalosporins (1.3%). 
Conclusions: Carbapenems showed maximum sensitivity for all urine isolates. The second and third options were polymyxin B and 
phosphonic acid derivatives, respectively. 
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I n t r o d u ct i on  
 
Urinary tract infection (UTI) is one of the most common 
bacterial infection in humans.1 The infection can be seen 
in any gender and age group.2 UTIs can be further 
grouped into hospital-acquired and community-acquired 
infections.3 The global statistics report concludes that in 
adult age group, urinary tract infections (UTIs) are more 
common in females due to their pelvic anatomy, and 
diverse physiological changes especially during 
pregnancy. However, in older age groups the chances of 
UTI are almost equal in females and males. In cases of 
males of older age group, the presence of benign 
prostatic hyperplasia is the top most etiological factor. 
Complicated UTIs can cause pyelonephritis, or even renal 
failure and end-stage renal disease. Severe UTI can lead 
to pre-term delivery and miscarriages in pregnant 
women.4 
 
Gram-positive and Gram-negative bacteria have a role in 
causing UTI, making it a common bacterial infection. The 
pathogenesis involves acquisition of genes by 
microorganisms, which encodes various mechanisms for 
antibiotic resistance of the organisms. Most important 
amongst those include gram-negative organisms 
ORIGINAL ARTICLE 
                   J Islamabad Med Dental Coll 2019 187 
producing extended-spectrum beta-lactamases (ESBLs), 
AmpC- β -lactamases, and carbapenemases.5 
 
UTI can cause enormous economic burden on the 
patients from low income communities, and contribute to 
poor quality of life during the course of the disease.6 
Irrational and haphazard use of extensive antibiotics is 
leading to an increase in antimicrobial resistance, 
especially in the developing countries.7,8 Hence, 
appropriate antibiotic use will not only decrease the 
resistance patterns in the UTI causing organisms but also 
help to eliminate the disease quickly, prevent 
complications and reduce the cost of treatment 
significantly.9 
 
The increased frequency and management of antibiotic 
resistance in urinary tract infection (UTI) is a challenging 
task for the clinicians globally. Therefore, the current 
study was planned to identify the microbial etiology of UTI 
and the most suitable antibiotics used for treatment. This 
will be helpful to review the empirical therapy and 
management protocols of UTI in our set-up. 
 
M a t e r i a l  a n d  M e t h od s  
This cross-sectional study was carried out at Al Sayed 
Hospital, Kidney Centre, Rawalpindi from June 30, 2018 
to January 30, 2019. A simple random sampling 
technique was used to enroll the participants. A sample 
size of 113 was calculated by taking 12% frequency of 
UTI in Pakistan,10 however, it was increased to 152 to 
increase the validity of the study. Both male and female 
patients of ≥18years of age, having a confirmed diagnosis 
of UTI based upon findings of urine routine examination 
(R/E) were included in the study. The presence of more 
than 10 pus cells in urine R/E were considered significant 
to label a patient as a suspected case of UTI.11 An 
informed consent was taken from all the enrolled 
participants to fulfil ethical considerations. The non-willing 
patients and those with normal urine R/E were excluded 
from the study. 
 
Three days of urine culture and sensitivity (C/S) were 
done as per recommended clinical laboratory standard 
institute (CLSI) guidelines for the year 2017.12 On first day 
the urine specimens were cultured on CLED agar (Oxoid 
company). Bacteuric test strips were used for the 
inoculation of urine culture on CLED agar, so that exact 
colony counts can be correlated. The CLED agar plates 
were than incubated at 37ºC for 24 hours. 
 
On second day the colony counts were correlated with 
number of pus cells. Gram staining was done to see the 
bacterial morphology. Bacterial identification was done by 
using analytical profile index (API-20 E) for biochemical 
testing. The antimicrobial sensitivity was applied on 
Mueller Hinton agar. 
 
For beta lactam group, Piperacilin (100µg), Augmentin 
(30µg), Ampicillin (10µg), and Oxacillin (1µg) discs were 
used. Amongst Glycopeptide group, Vancomycin disc 
(30µg) was used. From Quinolone group, ciprofloxacin 
(5µg), levofloxacin (5µg), norfloxacin (10µg), ofloxacin 
(1µg), pipemidic acid (20µg) discs were used. Amongst 
the Aminoglycoside group, amikacin (30µg) and 
gentamycin (10µg) discs were used.  A doxycycline disc 
(30 µg) was used from Tetracycline group. A 25µg disc of 
cotrimoxazole (nucleic acid inhibitors) was also used. 
Regarding cephalosporins, 30µg Cephradine disc was 
used from first-generation, Cefoxitin (30µg), Cefaclor 
(30µg), and Cefuroxime (30µg) discs from second-
generation cephalosporins, and Cefotaxime (30µg), 
Ceftriaxone (30 µg), Cefoperazone (75µg) and Cefixime 
(5µg) discs were used from third-generation 
cephalosporins. While from fourth-generation 
cephalosporins, Cefipime (30µg) disc was used. Amongst 
the carbapenem group, Imipenam disc of 10µg was used.  
A 30µg Linezolid disc was used from oxazolidinone 
group. Amongst phosphonic acid derivatives, a 
fosfomycin disc of 50µg was used. While 300µg 
Nitrofurantoin disc was used for imidazolidinedione group. 
More antibiotics used were tigecycline (15 µg), 
teicoplanin (30 µg), and polymyxin (50µg), respectively. 
 
On the third day, bacterial confirmation was done by 
interpreting the results of biochemical tests obtained from 
API-20E. The antimicrobial zone diameters were 
measured as per recommended CLSI guidelines, in order 
to label a drug as sensitive and resistant. 
 
The SPSS Version 16 was used for statistical analysis. 
Frequencies and percentages were calculated to assess 
the sensitivity rate, extended spectrum beta-lactamase 
producing organisms (ESBL), Vancomycin resistant 
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Enterococci (VRE) and Methicillin resistant 
Staphylococcus aureus (MRSA). 
 
R e s u l t s  
Out of 152 culture positive urine, most prevalent 
organisms was E. coli (n=81) followed by Klebsiella 
pneumoniae (n=25) (Table I). Regarding sensitivity 
pattern, E. coli (n=77), Klebsiella pneumoniae (n=25) and 
Pseudomonas aeruginosa (n=7) were found maximally 
sensitive to polymyxin B. Enterococcus faecalis showed 
maximum sensitivity (n=16) to Carbapenem, Teicoplanin 
and Glycylcycline (Tigecycline). Enterobacter cloacae 
revealed highest sensitivity (n=7) to Carbapenem and 
Phosphonic acid derivatives. Staphylococcus aureus was 
maximally sensitive (n=5) to Oxazolidinone and 
Tetracyclines (Table II A and B). 
 
Table I: Frequency of commonly prevalent organisms in urine 
isolates (n=152) 
Organisms 
belonging to ESBL 
group  
Total number 
 n (%) 
ESBL 
 n (%) 
E. coli 81 (53.3) 59 (72.8) 
Klebsiella 
pneumoniae 
25 (16.4) 21 (84) 
Enterobacter cloacae 8 (5.3) 1 (12.5) 
Pseudomonas 
aeruginosa 
7 (4.6) 0  
Morganella morganii 3 (2) 0  
Proteus mirabilis 2 (1.3) 1 (50) 
Burkholderia cepacia 1 (0.66) 0  
Serratia marcescens 1 (0.66) 0 
Organisms 
belonging to VRE & 
MRSA group  
Total number 
n (%) 
VRE 
n (%) 
MRSA 
n (%) 
Enterococcus 
faecalis  
18 (11.8) 1 (5.5) 0 
Staphylococcus 
aureus  
6 (3.9) 0 1 (16.6) 
 
ESBL - Extended-spectrum beta-lactamases; VRE – Vancomycin 
resistant Enterococci; MRSA – Methicillin resistant Staphylococcus 
aureus 
 
Considering overall sensitivity of antibiotics for the 
pathogens of urine culture, highest sensitivity was 
observed for Carbapenems (n=127), followed by 
Polymyxin B (n=110),  Phosphonic acid  derivatives 
(n=100), Aminoglycoside group (n= 100), extended 
spectrum penicillin (n= 96), Imidazolidinedione (n=91)  
and Tetracycline groups (n=91). The least sensitivity was 
observed for first-generation cephalosporins (n= 02), 
Tigecycline (n=16), Teicoplanin (n=21) and Oxazolidinone 
(linezolid) (n=22) (Figure 1) 
 
Amongst all the positive cultures, the highest sensitivity 
was observed for Carbapenems (n=127; 83.5%), 
Phosphonic acid derivatives (n=100; 65.8%) and 
polymyxin B (n=110; 72.3 %), respectively. This was 
followed by aminoglycoside group (n= 100; 65%) and 
extended spectrum penicillin (n= 96; 63.1%). Next in 
sequence are the imidazolidinedione and tetracycline 
groups (n=91; 59.8% for each) (Figure 1). The least 
sensitivity was observed for first-generation 
Cephalosporins (n= 02; 1.3 %), Tigecycline (n=16; 
10.5%), Teicoplanin (n=21; 13. 8%) and Oxazolidinone 
(Linezolid) (n=22; 14.4%), respectively (Figure 1). 
 
 
Figure 1: Overall sensitivity of antibiotic groups for 
pathogens in urine culture (n=152) 
 
D i s c u s s i o n  
Urinary tract infections (UTIs) accounts for highly 
prevalent infection around the globe. It has been reported 
that annually 150 million people present with this infection 
worldwide.13 A study conducted in Denmark on 
prescription for UTI concluded that amongst all bacterial 
infections, prevalence of UTI is 89.5%.  
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Table II A: Sensitivity pattern of different microbial isolates from urine cultures (n=152) 
Antibiotics  Escherichia coli  
(n=81) 
n (%) 
Klebsiella 
pneumoniae 
(n=25) 
n (%) 
Enterococcus 
faecalis 
(n=18) 
n (%) 
Enterobacter 
cloacae 
 (n=08) 
n (%) 
Pseudomonas 
aeruginosa 
(n=07) 
n (%) 
Extended spectrum Penicillin 63 (77.7) 04 (16) 14 (77.8) 01 (12.5) 05 (71.4) 
Short acting penicillin 10 (12.3) 04 (16) 12 (66.7) 0 0 
Aminoglycosides 71 (87.6) 15 (60) 0 01 (12.5) 05 (71.4) 
Fluoroquinolones 26 (32) 04 (16) 0 0 05 (71.4) 
Sulphonamides 21 (25.9) 3 (12) 0 01 (12.5) 0 
Carbapenem 70 (86.4) 23 (92) 16 (88.9) 07 (87.5) 05 (71.4) 
Phosphonic acid derivative  71 (87.6) 08 (32) 14 (77.7) 07 (87.5) 0 
Oxazolidinone 0 0 16 (88.9) 01 (12.5) 0 
Imidazolidinedione 65 (80.2) 10 (40) 12 (66.6) 0 0 
Tetracyclines 61 (75.3) 10 (40) 15 (83.3) 0 0 
1st Generation Cephalosporins 0 0 02 (11.1) 0 0 
2nd Generation Cephalosporins 22 (27.1) 0 0 0 0 
3rd Generation Cephalosporins 22 (27.1) 0 0 0 06 (85.7) 
4 th Generation Cephalosporins 22 (27.1) 04 (16) 0 0 05 (71.4) 
Polymyxin B 77 (95.06) 25 (100) 0 01 (12.5) 07 (100) 
Teicoplanin 0 0 16 (88.9) 0 0 
Glycylcycline (Tigecycline) 0 0 16 (88.9) 0 0 
  
Table II- B: Sensitivity pattern of different microbial isolates from urine cultures (n=152) 
Antibiotics  Staphylococcus 
aureus  
(n=06) 
n (%) 
Morganella 
morganii 
(n=03) 
n (%) 
Proteus 
 mirabilis 
(n=02) 
n (%) 
Burkholderia 
cepacia  
(n=01) 
n (%) 
Serratia 
marcescens  
(n=01) 
n (%) 
Extended spectrum Penicillin 04(66.7) 03(100) 01(50) 0 01(100) 
Short acting Penicillin 04(66.7) 0 01(50) 0 0 
Aminoglycosides 03(50) 02(66.7) 02(100) 0 01(100) 
Fluoroquinolones - 0 01(50) 01(100) 01(100) 
Sulphonamides 03(50) 02(66.7) 01(50) 01(100) 01(100) 
Carbapenem 0 02(66.7) 02(100) 01(100) 01(100) 
Phosphonic acid derivative  0 0 0 0 0 
Oxazolidinone 05(83.3) 0 0 0 0 
Imidazolidinedione 04(66.7) 0 0 0 0 
Tetracyclines 05(83.3) 0 0 0 0 
1st Generation Cephalosporins 0 0 0 0 0 
2nd Generation Cephalosporins 04(66.7) 0 0 0 0 
3rd Generation Cephalosporins 0 02(66.7) 01(50) 0 01(100) 
4 th Generation Cephalosporins 0 03(100) 0 0 01(100) 
Polymyxins B 0 0 0 0 0 
Teicoplanin 04(66.7) 0 0 01(100) 0 
Glycylcycline (Tigecycline) 0 0 0 0 0 
 
The appropriate choice for empirical management of UTI 
is always a challenging task for the clinicians Many 
national and internationally published studies support the 
fact that the selection of antibiotic should vary based upon 
the nature of UTI, acute lower or upper UTI, recurrent  
 
UTI, or a case of complicated UTI.13 In the current study 
results showed that Escherichia coli infection was most 
common (55.4%) followed by Klebsiella pneumoniae 
(17.1%), and Enterococcus faecalis infection (12.3%). 
Only few cases were of Burkholderia cepacia and Serratia 
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marcescens were reported. These findings are in line with 
the published data which also showed that Escherichia 
coli, Klebsiella pneumoniae, Proteus mirabilis, 
Enterococcus faecalis and Staphylococcus saprophyticus 
are the main causative organisms for UTI.9,10,14 A 
Canadian study revealed the same prevalence of 
uropathogens with the highest frequency seen for gram-
negative rods (91.8%) mainly the Enterobacteriaceae 
family.15 The most common organisms included 
Escherichia coli (39.7%), Klebsiella pneumoniae (15.8%) 
Pseudomonas aeruginosa (13.8%), Proteus mirabilis 
(10.6%) and Acinetobacter baumannii (5%).15 
 
We also reported the presence of resistant 
microorganisms like ESBL, VRE and MRSA. ESBL 
producing Escherichia coli and Klebsiella pneumoniae 
were seen in 72.8% and 84% cases respectively. VRE 
producing Enterococcus faecalis was seen in 5.5% cases, 
while MRSA was seen in 16.6% cases. This is in 
agreement with the results of a published study where, 
Nitrofurantoin and Fosfomycin were the recommended 
first line treatment options for uncomplicated bacterial 
cystitis, while the fluoroquinolones and β-lactams were 
amongst the second line options.15 The results are 
different from another study conducted in Denmark, 
where Pivmecillinam hydrochloride (extended-spectrum 
penicillin) was the first line management option for both 
lower or upper UTI.13 According to published data of 
various European countries, the identified frequency of 
ESBLs range from 70–100% , meaning that carbapenems 
often represent the only active available antibiotics.16 
 
Amongst all the positive cultures, the highest sensitivity 
was observed for carbapenems, followed by Polymyxin B, 
phosphonic acid derivatives, aminoglycoside group, 
extended spectrum penicillins, imidazolidinedione and 
tetracycline groups. This finding is similar to another study 
in which treatment options for UTIs with or without 
ESBLs-producing Enterobacteriaceae include 
nitrofurantion, fosfomycin, fluoroquinolones, cefoxitin, 
piperacillin-tazobactam, carbapenems, ceftolozane-
tazobactam, ceftazidime-avibactam, and 
aminoglycosides.13 The same study also reported that 
fosfomycin, Ceftazidime-avibactam, polymyxin B, 
aztreonam, colistin, aminoglycosides, and tigecycline are 
treatment options for UTIs caused by carbapenem-
resistant Enterobacteriaceae (CRE).13 Another study by 
Alamri et al also support the results of current study by  
reporting that fosfomycin, nitrofurantoin and pivmecillinam  
can be the first line management options for treating 
uncomplicated UTIs.17 Hence, ceftolozane/tazobactam are 
the approved antibacterial for empirical treatment of  UTI 
and pyelonephritis in adults.17,18 Many relevant studies 
and trials have concluded that fosfomycin and 
Nitrofurantoin are still the magic bullets to treat any type 
of UTI.19,20 With Fosfomycin found to be the most reliable 
option for managing any type of UTI, whether complicated 
or non-complicated.14,21 A systematic literature review 
between 1946 to 2015 revealed that Nitrofurantoin 
harbors the properties of sterilizing urine and prevent the 
occurrence of UTI.22,23 However, the only point of concern 
regarding its prolonged use is severe gastrointestinal side 
effects.24 The results of current study showed that 94.1% 
cases of Enterococcus feacalis cases were found 
sensitive to tigecycline. The efficacy of tigecycline for UTI 
has not been extensively studied. Although a meta-
analysis concluded that it is a good treatment option for 
multi-drug resistant (MDR) Gram-negative UTIs.25 
Tigecycline is known to play a significant role in cases of 
UTI associated with polycystic kidney disease, impaired 
renal function and renal transplant.26 
 
Our study showed least sensitivity for first-generation 
cephalosporins, tegicycline, teicoplanin, and 
Oxazolidinone (linezolid). This is in contrast to the 
published data which shows increased sensitivity of 
uropathogens to linezolid, daptomycin, and vancomycin.15 
Similar findings were observed in another study which 
concluded that all Enterococci and Staphylococci harbor 
great sensitivity for linezolid, fosfomycin, vancomycin and 
teicoplanin.27 A Sri Lankan study reported that 95-100% 
ESBL producing organisms were sensitive to 
carbapenems, especially meropenem. Therefore, this 
group can also be used as first-line therapy for 
complicated UTIs.28 Moreover, the intravesical efficacy of 
gentamycin showed significant results in reducing the 
frequency of recurrent UTIs.29 
 
The management options for ESBL producing organisms 
is biggest health challenge around the globe.30 A case 
series reported better outcomes for prophylactic use of a 
combination preparation, ceftibuten plus amoxicillin-
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clavulanic acid, ceftolozane/tazobactam and tegicycline 
even in ESBL producing organisms.31-33 Therefore, 
knowledge about the commonly prevalent organisms and 
their susceptibility pattern can serve as an essential 
requirement for accurate management of urinary tract 
infections.34 Thus, the morbidity and mortality rates can be 
reduced due to proper management of complicated UTIs. 
 
C o n c l u s i on  
Carbapenems showed maximum sensitivity for all urine 
isolates. The second and third options were polymyxin B 
and phosphonic acid derivatives, respectively. 
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